Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells

Esther Z. Chen, Blake A. Jacobson, Manish R. Patel, Aniekan M. Okon, Shui Li, Kerry Xiong, Abhishek J. Vaidya, Peter B. Bitterman, Carston R. Wagner, Robert A. Kratzke

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Deranged cap-mediated translation is implicated in the genesis, maintenance and progression of many human cancers including mesothelioma. In this study, disrupting the eIF4F complex by antagonizing the eIF4E-mRNA-cap interaction is assessed as a therapy for mesothelioma. Mesothelioma cells were treated with 4Ei-1, a membrane permeable prodrug that when converted to the active drug, 7-benzyl guanosine monophosphate (7Bn-GMP) displaces capped mRNAs from the eIF4F complex. Colony formation was measured in mesothelioma treated with 4Ei-1 alone or combined with pemetrexed. Proliferation was examined in cells treated with 4Ei-1. Binding to a synthetic cap-analogue was used to study the strength of eIF4F complex activation in lysates exposed to 4Ei-1. 4Ei-1 treatment resulted in a dose dependent decrease in colony formation and cell viability. Combination therapy of 4Ei-1 with pemetrexed further reduced colony number. Formation of eIF4F cap-complex decreased in response to 4Ei-1 exposure. 4Ei-1 is a novel prodrug that reduces proliferation, represses colony formation, diminishes association of eIF4F with the mRNA cap, and sensitizes mesothelioma cells to pemetrexed.

Original languageEnglish (US)
Pages (from-to)598-603
Number of pages6
JournalInvestigational New Drugs
Issue number4
StatePublished - Aug 2014


  • 4Ei-1
  • 7-benzyl guanosine monophosphate
  • Cap-dependent translation
  • Mesothelioma
  • eIF4E


Dive into the research topics of 'Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells'. Together they form a unique fingerprint.

Cite this